Belite Bio price target raised to $100 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $100 from $60 and keeps a Buy rating on the shares following the Q3 report. Considering the annual price range of Syfovre and Izerway between $13,000 and $26,000, the firm updated its projected price for tinlarebant from $6,000 to $9,500 in the model.